• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International symposium on controlled release of bioactive materials >A new multiparticulate formulation of 5-aminosalicylic acid (5-asa) for the treatment of crohn's disease
【24h】

A new multiparticulate formulation of 5-aminosalicylic acid (5-asa) for the treatment of crohn's disease

机译：用于治疗克罗恩病的5-氨基水杨酸（5-ASA）的新多颗粒制剂

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Crohn's disease (CD) is an inflammatory disease of the mucosal tissue in the small intestine of unknown etiology. The terminal ileum is most frequently affected, but the whole small intestine can be involved. Local therapy of CD calls for continuous release of drug through- our the small intestine. The aim of this work was to develop an oral multiple unit dosage form which possesses the desired release profile. 5-ASA-containing pellets were coated with a diffusion controlled polymer consisting of EUDRAGIT direct R RL, a swellable, polymethacrylate-based polymer. The amount of polymer applied was optimized to attain an appropriate formulation. Reproducibility of the formulation was then examined using the similarity factor (f_2)~1.
机译：克罗恩病（CD）是未知病因的小肠中粘膜组织的炎症疾病。终端回肠最常受到影响，但整个小肠都可以涉及。 CD局部治疗呼吁通过 - 我们的小肠连续释放药物。这项工作的目的是开发一种口腔口腔多单位剂型，其具有所需的释放曲线。用eUdragit直接R R1组成的扩散控制聚合物，溶胀，聚甲基丙烯酸酯基聚合物组成的含5-ASA的粒料。施加的聚合物的量优化以获得适当的制剂。然后使用相似因子（F_2）〜1检查制剂的再现性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号